Skip to main content
SpringerLink
Log in

Lower toxicity with targeted anticancer agents in phase I trials

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Molife LR, Alam S, Olmos D, Puglisi M, Shah K, Fehrmann R, Trani L, Tjokrowidjaja A, De Bono JS, Banerji U, Kaye SB.Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Annals of Oncology 23: 1968-1973, No. 8, 1 Aug 2012. Available from: URL: http://dx.doi.org/10.1093/annonc/mds030

  2. Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R.Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Annals of Oncology 23: 1963-1967, No. 8, 1 Aug 2012. Available from: URL: http://dx.doi.org/10.1093/annonc/mds027

  3. Greystoke A, Ranson M.Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Annals of Oncology 23: 1934-1936, No. 8, 1 Aug 2012. Available from: URL: http://dx.doi.org/10.1093/annonc/mds116

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lower toxicity with targeted anticancer agents in phase I trials. React. Wkly. 1416, 3 (2012). https://doi.org/10.2165/00128415-201214160-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214160-00005

Keywords

Search

Navigation